Sabiia Seb
PortuguêsEspañolEnglish
Embrapa
        Busca avançada

Botão Atualizar


Botão Atualizar

Ordenar por: 

RelevânciaAutorTítuloAnoImprime registros no formato resumido
Registros recuperados: 7
Primeira ... 1 ... Última
Imagem não selecionada

Imprime registro no formato completo
Contribution of gliotoxin to aspergillosis OAK
豊留, 孝仁; TOYOTOME, Takahito.
Aspergillus species (spp.) are medically important pathogens that cause aspergillosis, and A. fumigatus is the most prevalent causative agent of the disease. Aspergillus spp. produce various secondary metabolites; however, the role of these metabolites in aspergillosis remains unclear. Gliotoxin is a major secondary metabolite produced by A. fumigatus. Several recent studies have reported that gliotoxin contributes to the virulence of A. fumigatus. Here I review studies related to gliotoxin and its contribution to the infection caused by A. fumigatus.
Palavras-chave: Aspergillosis; Aspergillus fumigatus; Gliotoxin; Secondary metabolite.
Ano: 2015 URL: http://ir.obihiro.ac.jp/dspace/handle/10322/4157
Imagem não selecionada

Imprime registro no formato completo
Causative Agents of Aspergillosis Including Cryptic Aspergillus Species and A. fumigatus OAK
豊留, 孝仁; TOYOTOME, Takahito.
アスペルギルス症は深在性真菌感染症の重要な位置を占めている.アスペルギルス症の原因真菌はAspergillus fumigatusが最も重要であるが,そのほかにもAspergillus flavusやAspergillus niger, Aspergillus terreusなども重要な原因菌種である.また,近年になって隠蔽種と呼ばれる各Aspergillus sectionの代表的な種に非常によく似た菌種の存在が認識され,一部のアスペルギルス症の原因となっていることも分かってきた.最近の研究で,それらの菌種間では抗真菌薬に対する感受性や二次代謝産物の産生プロファイル (エクソメタボローム) が異なることも明らかとなってきた.一方,治療中のA. fumigatusアゾール耐性化や近年の欧州を中心とした環境中アゾール耐性A. fumigatusの出現も報告され,これら菌種を正確に同定し,加えて感受性を評価することの重要性が高まってきている. 本総説ではA. fumigatusを含めたアスペルギルス症原因菌種,特に隠蔽種について触れ,エクソメタボローム解析を利用した同定の可能性を述べる.加えて,A. fumigatusアゾール系抗真菌薬耐性について最近の報告を交えて概説したい
Palavras-chave: Aspergillosis; Aspergillus spp.; Azole resistance; Cryptic species; Secondary metabolites.
Ano: 2016 URL: http://ir.obihiro.ac.jp/dspace/handle/10322/4396
Imagem não selecionada

Imprime registro no formato completo
Antifungal pharmacodynamics: Latin America's perspective BJID
Gonzalez,Javier M.; Rodriguez,Carlos A.; Agudelo,Maria; Zuluaga,Andres F.; Vesga,Omar.
Abstract The current increment of invasive fungal infections and the availability of new broad-spectrum antifungal agents has increased the use of these agents by non-expert practitioners, without an impact on mortality. To improve efficacy while minimizing prescription errors and to reduce the high monetary cost to the health systems, the principles of pharmacokinetics (PK) and pharmacodynamics (PD) are necessary. A systematic review of the PD of antifungals agents was performed aiming at the practicing physician without expertise in this field. The initial section of this review focuses on the general concepts of antimicrobial PD. In vitro studies, fungal susceptibility and antifungal serum concentrations are related with different doses and dosing...
Tipo: Info:eu-repo/semantics/article Palavras-chave: Antifungal agents; Pharmacology; Pharmacodynamics; Pharmacokinetics; Candidiasis; Aspergillosis.
Ano: 2017 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702017000100079
Imagem não selecionada

Imprime registro no formato completo
Galactomannan use in clinical practice: providing free testing is not the full answer BJID
dos Santos,Jeniffer S.; Hermes,Djuli M.; Pasqualotto,Alessandro C..
ABSTRACT Introduction: Invasive aspergillosis is a condition associated with a high mortality rate mostly due to difficulties in performing an early diagnosis. In recent years, galactomannan detection has markedly improved the diagnosis of invasive aspergillosis, but very little is known on how physicians deal with this test in clinical practice. Methods: This cross-sectional study aimed to analyze the indications for the use of serum galactomannan in a large Brazilian hospital, between 2015 and 2016. No specific protocol was in place for GM request. We reviewed the medical records of adult (>18 years-old) patients who were tested for galactomannan due to one the following indications: screening, diagnosis, or treatment follow-up. Additional variables...
Tipo: Info:eu-repo/semantics/article Palavras-chave: Aspergillus; Aspergillosis; Opportunistic infections; Diagnosis; Tomography; Neutropenia; Immunosuppressed.
Ano: 2018 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702018000100037
Imagem não selecionada

Imprime registro no formato completo
Invasive intracranial aspergillosis spread by the pterygopalatine fossa in an immunocompetent patient BJID
Xiao,Anqi; Jiang,Shu; Liu,Yi; Deng,Kaihong; You,Chao.
Aspergillosis of the central nervous system (CNS) is an uncommon infection, mainly found in immunocompromised patients but rarely seen among immunocompetent patients. Herein we describe a 57 year-old immunocompetent man who suffered intracranial aspergillosis spread by the pterygopalatine fossa (PPF) following a tooth extraction. Based on magnetic resonance imaging (MRI) characteristics, in this report we focus on the spreading routes of CNS aspergillosis via communicative structures of the PPF, the relationship between clinical manifestations and the locations of the lesion, and propose a therapeutic strategy to improve the prognosis.
Tipo: Info:eu-repo/semantics/report Palavras-chave: Aspergillosis; Pterygopalatine fossa; Magnetic resonance imaging.
Ano: 2012 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702012000200016
Imagem não selecionada

Imprime registro no formato completo
Galactomannan detection from piperacillin-tazobactam brands available in the Brazilian market BJID
Xavier,Melissa Orzechowski; Pasqualotto,Alessandro Comarú; Aquino,Valério Rodrigues; Sukiennik,Teresa Cristina Teixeira; Severo,Luiz Carlos.
Piperacillin-tazobactam is a broad spectrum antimicrobial agent that can cause false-positive results in the commercial Platelia Aspergillus EIA test. So far, no study has been performed in Latin America to evaluate the clinical implication of this finding. Here we studied the potential for galactomannan detection in piperacillin-tazobactam batches commercialized in the Brazilian market. Five batches from distinct laboratories were tested in duplicate in the Platelia Aspergillus EIA according to the manufacturer's instructions. Only one drug showed crossreaction at a cut-off of 0.5. Human serum was spiked with this particular drug aiming to mimic achievable piperacillin-tazobactam concentrations in the serum. Results were all negative for galactomannan...
Tipo: Info:eu-repo/semantics/article Palavras-chave: Piperacillin-tazobactam; Aspergillosis; Platelia Aspergillus; Galactomannan.
Ano: 2009 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702009000500007
Imagem não selecionada

Imprime registro no formato completo
Aspergillosis: a limiting factor during recovery of captive magellanic penguins BJM
Xavier,Melissa O.; Soares,Mauro P.; Meinerz,Ana Raquel M.; Nobre,Márcia O.; Osório,Luiza G.; Silva Filho,Rodolfo P. da; Meireles,Mário Carlos A..
The article describes the epidemiology, macroscopic and histological lesions as well as the isolation of Aspergillus flavus and A. fumigatus from Magellanic penguins (Spheniscus magellanicus) during recovery in the Center for Recovery of Marine Animals (CRAM - 32ºS/52ºW), over a period of two years. From January 2004 to December 2005 the Center received 52 Magellanic penguins, and 23% (12/52) died. Necropsies were performed and tissue samples were collected for histological and microbiological examination. From 12 dead animals, aspergillosis was confirmed in five animals, corresponding to 42% of the mortality. Granulomatous nodules were observed mainly on air sacs and lungs. Histologically, septate and branching hyphae, measuring 3-5 µm and PAS positive...
Tipo: Info:eu-repo/semantics/article Palavras-chave: Aspergillosis; Rehabilitation; Penguins; Captivity.
Ano: 2007 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1517-83822007000300018
Registros recuperados: 7
Primeira ... 1 ... Última
 

Empresa Brasileira de Pesquisa Agropecuária - Embrapa
Todos os direitos reservados, conforme Lei n° 9.610
Política de Privacidade
Área restrita

Embrapa
Parque Estação Biológica - PqEB s/n°
Brasília, DF - Brasil - CEP 70770-901
Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco

Valid HTML 4.01 Transitional